CA-GLOBALLOGIC
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Cybereason, the leader in operation-centric attack protection, to help develop its next-generation cyber security platform and services. Deployed by large enterprises, governments, and major cloud providers worldwide, Cybereason’s future-ready attack protection spans across endpoints, the enterprise, the cloud, and everywhere the defenders battle cyber criminals. The collaboration will draw on GlobalLogic’s broad and deep expertise in security and data management software across devices through to the cloud, including the integration of advanced artificial intelligence (AI).
The program is one of the largest won by GlobalLogic in this field to date. It requires quickly scaling to hundreds of specialized engineers supporting Cybereason’s development roadmap over the next year. This program scope highlights the market’s need for stronger, better cybersecurity as cloud use, network expansions and other technology usage continued their upward trend and surged during the pandemic.
“Cyber threats have become considerably more frequent and sophisticated in recent years. We’ve become dangerously more vulnerable in areas traditional security solutions could not adequately protect—the network and the cloud,” said Rajaram Radhakrishnan, CRO, GlobalLogic. “Having operated in the cybersecurity space for more than a decade, GlobalLogic has become adept at successfully responding to complex requirements. Cybereason is a premier example of a crucial innovator building disruptive defense solutions, redefining what government-grade protection can be. We are honored to now be a part of their team.”
Cybereason delivers the most comprehensive protection available on the market today, analyzing more than 23 trillion security-related events per week—five times the volume of any other market solution. Using its patented Malicious Operations (MalOps™) engine, Cybereason reveals the full attack story across every device, user identity, application, and cloud deployment. One of Cybereason’s key solutions delivering this capability is the company’s Extended Detection and Response (XDR) solution —a unified detection and response tool that thwarts malicious operations across the entire IT stack. XDR is one of the several advanced technologies that GlobalLogic’s team will help Cybereason develop and enhance through the partnership.
“Cybereason’ operation-centric security approach is helping defenders combat sophisticated and persistent threats to their organizations. While other companies have security analysts chasing alerts without offering valuable insight, Cybereason helps organizations around the world leverage our award-winning technology each day to outthink and outpace attackers,” said Sam Curry, Chief Security Officer, Cybereason. “GlobalLogic’s track record along with its responsiveness and collaborative approach to R&D stood out as major factors in finalizing our partnership. Together, we will deliver next-gen cyber defense solutions that will help technology users better control their sensitive data and operations—no matter where they reside.”
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
About Cybereason
Cybereason (www.cybereason.com ) is the champion for today’s cyber defenders, providing operation-centric attack protection that unifies security from the endpoint to the enterprise, to everywhere the battle moves. The Cybereason Defense Platform combines the industry’s top-rated AI-powered detection and response (EDR and XDR), next-gen antivirus (NGAV), Anti-Ransomware Protection and Proactive Threat Hunting to deliver context-rich analysis of every stage of a MalOp™ (malicious operation). Cybereason is a privately held, international company headquartered in Boston with customers in more than 40 countries.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005650/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
